Ultragenyx Pharma (RARE) Misses Q2 EPS by 16c, beats revenue

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($2.25), $0.16 worse than the analyst estimate of ($2.09). Revenue for the quarter came in at $108.3 million versus the consensus estimate of $107.1 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c